XW023W7
Introduction Muscle to New Technology Group 7 with COVID-19 Vaccine Booster, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 2 Muscle |
| Approach | 3 Percutaneous |
| Device | W COVID-19 Vaccine Booster |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Muscle
Muscle tissue, whether skeletal or otherwise, is targeted for Introduction procedures when a New Technology substance is delivered directly into the muscular layer rather than the skin or subcutaneous fat above it. This route is used for agents intended to act locally within muscle or to achieve absorption through a highly vascular tissue bed, and it differs mechanically and pharmacokinetically from more superficial injection routes. Because muscle groups vary widely in size, depth, and blood supply across the body, the specific site chosen can affect both technique and the rate at which the introduced substance takes effect. This code is reserved for substances qualifying as New Technology, such as investigational or recently approved biologic agents, rather than routine intramuscular medications.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: COVID-19 Vaccine Booster
This value denotes administration of a COVID-19 vaccine booster dose, given after completion of the primary vaccination series to restore or extend immune protection over time. It is distinguished from the first, second, and third dose codes, which apply to doses within or supplementing the primary series, by representing a separate, later administration intended to boost waning immunity rather than complete initial vaccination.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.